Abstract
Background: The present meta-analysis was performed to evaluate theprognostic and clinicopathological significance of PD-L1in anal cancer (AC). Methods: Hazard ratios (HRs) and 95%CIsregarding overall survival (OS) and progression-free survival (PFS) were calculated based on PD-L1 levels. Results: According to the combined data, PD-L1 showed no significant relationship with OS (HR=0.76; 95%CI=0.35-1.67; p=0.502) or PFS (HR=0.88; 95%CI=0.35-2.33; p=0.789) in patients with AC. Based on subgroup analysis, PD-L1 overexpression significantly predicted prolonged OS (HR=0.38; 95%CI=0.17-0.84; p=0.017) in tumor node metastasis stages I-III and inferior PFS (HR=2.73; 95%CI=1.32-5.65; p=0.007) inpatients with stage I-IV AC. Conclusion: PD-L1 level assessed by immunohistochemistry did not significantly predict survival outcomes inAC cases.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
